ZA202204423B - Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies - Google Patents

Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies

Info

Publication number
ZA202204423B
ZA202204423B ZA2022/04423A ZA202204423A ZA202204423B ZA 202204423 B ZA202204423 B ZA 202204423B ZA 2022/04423 A ZA2022/04423 A ZA 2022/04423A ZA 202204423 A ZA202204423 A ZA 202204423A ZA 202204423 B ZA202204423 B ZA 202204423B
Authority
ZA
South Africa
Prior art keywords
antibodies
methods
combination
cancer treatment
pdl1
Prior art date
Application number
ZA2022/04423A
Other languages
English (en)
Inventor
Ye Liu
Beibei Jiang
Xiaomin Song
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of ZA202204423B publication Critical patent/ZA202204423B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2022/04423A 2019-11-21 2022-04-20 Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies ZA202204423B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019120055 2019-11-21
PCT/CN2020/130075 WO2021098774A1 (en) 2019-11-21 2020-11-19 Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies

Publications (1)

Publication Number Publication Date
ZA202204423B true ZA202204423B (en) 2023-01-25

Family

ID=75981031

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/04423A ZA202204423B (en) 2019-11-21 2022-04-20 Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies

Country Status (12)

Country Link
US (1) US20230212291A1 (https=)
EP (1) EP4061850A4 (https=)
JP (1) JP2023503396A (https=)
KR (1) KR20220103708A (https=)
CN (1) CN115151563A (https=)
AU (1) AU2020386583A1 (https=)
BR (1) BR112022009147A2 (https=)
CA (1) CA3156931A1 (https=)
IL (1) IL293119A (https=)
MX (1) MX2022006147A (https=)
WO (1) WO2021098774A1 (https=)
ZA (1) ZA202204423B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566935B (zh) 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
CN121285385A (zh) 2023-05-12 2026-01-06 金麦安博股份有限公司 能够与ox40结合的抗体、其变体及其用途
WO2024240247A1 (en) * 2023-05-25 2024-11-28 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 antibodies
TW202540189A (zh) * 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800503T1 (it) * 2013-03-18 2018-11-09 Janssen Pharmaceuticals Inc Anticorpi anti-cd (ox40) umanizzati e loro usi
EA034666B1 (ru) * 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
AU2014364606A1 (en) * 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
TWI726608B (zh) * 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
TN2019000101A1 (en) * 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
WO2017021911A1 (en) * 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
CN111542544A (zh) * 2017-11-01 2020-08-14 百时美施贵宝公司 用于治疗癌症的免疫刺激性激动性抗体
CN112566935B (zh) * 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法

Also Published As

Publication number Publication date
MX2022006147A (es) 2022-06-17
WO2021098774A1 (en) 2021-05-27
CN115151563A (zh) 2022-10-04
US20230212291A1 (en) 2023-07-06
EP4061850A4 (en) 2024-03-20
EP4061850A1 (en) 2022-09-28
AU2020386583A1 (en) 2022-06-02
CA3156931A1 (en) 2021-05-27
KR20220103708A (ko) 2022-07-22
BR112022009147A2 (pt) 2022-07-26
JP2023503396A (ja) 2023-01-30
IL293119A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
IL313807A (en) Claudin 18 antibodies and methods for cancer treatment
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
ZA202204423B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
IL279251A (en) Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
IL276303A (en) Methods of treating cancer with ANTI-PD-1 antibodies
LT4339615T (lt) Antikūnai prieš pd-1, skirti naudoti vėžio gydymui
IL274766A (en) Human anti-LIV1 antibodies for the treatment of breast cancer
IL275940A (en) Combined treatment with antibodies against IL-8 and against PD-1 for cancer treatment
IL281441B (en) Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer
IL304600A (en) Methods for treating cancer using anti-tigit antibodies in combination with anti-pd1 antibodies
ZA202204422B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
IL289842A (en) Human anti-liv1 antibodies for cancer therapy
IL286337A (en) Cancer treatment with her2xcd3 bispecific antibodies in combination with anti-her2 mab
IL280830A (en) Bracelets for use in cancer treatment methods
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
ZA202204252B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
HK40072365A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
ZA202108220B (en) Association of polyclonal antibodies and anti-pd1 or anti-pdl1 antibodies for the treatment of cancer
EP4061844A4 (en) METHODS OF TREATING CANCER WITH ANTI-OX40 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY AGENTS
HK40072366A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
HK40103626A (en) Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies
SG11202103148QA (en) Methods of treating residual breast cancer with trastuzumab emtansine
HK40028770A (en) Compositions and methods for treating cancer with anti-egfr antibodies